TheSUBWAY.com - Pre-Market Alerts - PSTI - AASI

Pluristem Therapeutics, Inc (NASDAQ: PSTI) - Pluristem’s PLX-MS Shows Potential Benefit in the Prevention of Multiple Sclerosis

AASI - All Asia Licensing, Inc. (Pink Sheets: AASI) - Announces Proposed Joint Venture with Bio Research Firm for Bovine Testing, Beef Grading !

<!--[if supportFields]> DATE \@ "MMMM d, yyyy" < ![endif]--> August 11, 2008 <!--[if supportFields]> < ![endif]--> - TheSUBWAY: Announces the following stocks to its Pre Market Standouts List: All Asia Licensing, Inc. (Pink Sheets: AASI), Pluristem Therapeutics, Inc (NASDAQ: PSTI).

Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT) a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that the Company’s PLacental eXpanded (PLX-MS) cells have demonstrated in vivo efficacy in the prevention of Multiple Sclerosis (MS). PLX cells are Pluristem’s placental-derived mesenchymal stromal cells (MSCs) that have been expanded in the Company’s proprietary PluriX(TM) 3-D bioreactor.

In a further analysis aiming to demonstrate the in vivo efficacy of PLX-MS cells for the prevention of MS, Experimental Autoimmune Encephalitis (EAE) was induced in mice via immunization with the MOG35-55 protein on day 0. EAE is an autoimmune inflammatory disease of the CNS that represents the paradigmatic model for MS. The animals then received, on day 8, intravenously either PLX-MS or PlasmaLyte, which served as a control. PLX-MS administration prevented the appearance of clinical symptoms and signs associated with MS throughout the 35-day study period compared to those animals receiving the control. Additionally, the beneficial effects were similar to when Zappia et. al. used MSCs that were non-placental in origin in this EAE animal model(1).

All Asia Licensing Inc. (Pink Sheets:AASI), Friday announced that it entered into a Letter of Intent with an international bio research and marketing firm to manufacture and distribute in China the research company’s proprietary cattle test for BSE (Bovine Spongiform Encephalopathy), better known as “Mad Cow” Disease.

“Assuming the consummation of a final agreement, I would anticipate that the 50-50 sharing arrangement may result in annual revenue between $100 million and $150 million for All Asia once the system is rolled out across China,” according to Anthony Lee, CEO of All Asia Licensing.

The Letter of Intent provides for the creation of a joint venture company later in the month in the Peoples Republic of China. There, the beef industry is governed by the Ministry of Agriculture, which has oversight over approximately 60 million head of cattle in beef processing plants at any one time. The joint venture will deal directly with the National Diagnostic Center for Exotic Animal Diseases, the national research laboratory for BSE and Newcastle Disease.

Read the Full Release & Visit TheSUBWAY’s Investor Forum Here:

PSTI NEWS - http://investor-forum.thesubway.com/small-cap-forum/showtopic...

AASI NEWS - http://investor-forum.thesubway.com/small-cap-forum/showtopic...

TheSUBWAY.com’s Daily Stock Updates:

TheSUBWAY.com highlights stocks that are in the news, have traded high volume, or experienced a large change in price in recent sessions.  The aforementioned commentary is not meant to be indicative of a “long term” view of any of the companies listed.

About TheSUBWAY.com :

TheSUBWAY.com, a leader in corporate communications and finance, provides all investors with a wide-ranging set of financial tools, including original stock market commentary, stock quotes, interactive charts, portfolio watch, live chat and message boards, etc., plus the latest news, press releases, investment opinions, and research reports for all companies highlighted on the site. For more daily commentary, go to http://www.thesubway.com

TheSubway.com is consistently ranked in the top 4 on the StockPromoters.com “Best performing promoters of all time” list.  This is out of over 1,000 promoters and promotional campaigns tracked by StockPromoters.com.  Visit http://www.StockPromoters.com for more details.

All material herein was prepared by CRG Partners, Inc. (CRGP) based upon information believed to be reliable. The information contained herein is not guaranteed by CRGP to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRGP is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRGP has been compensated three hundred thousand shares for AASI. CRGP intends to sell its shares. CRGP has sold approximately zero AASI shares to date.  CRGP may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRGP and its web site operates under a license from Capital Research Group, Inc., TheSUBWAY.com Inc. and One Source Solutions Inc. (Licensors) and CRGP is not the agent of any of the Licensors and CRGP is solely responsible for all statements made herein.  CRGP’s Licensors, affiliates, officers, directors and employees own shares and intend to buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. CRGP will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.

Joe Farrar, President, CRG Partners, Inc.
631.935.4728
www.TheSUBWAY.com